NASDAQ:BLCMBellicum Pharmaceuticals Stock Price, Forecast & News

Bellicum Pharmaceuticals' stock was trading at $7.29 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BLCM stock has increased by 5.5% and is now trading at $7.69. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bellicum Pharmaceuticals.

Bellicum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Bellicum Pharmaceuticals.

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) posted its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, topping the Zacks' consensus estimate of ($2.73) by $3.82. Bellicum Pharmaceuticals had a negative return on equity of 664.19% and a negative net margin of 1,574.65%. View Bellicum Pharmaceuticals' earnings history.

Bellicum Pharmaceuticals's stock reverse split before market open on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 5th 2020. An investor that had 100 shares of Bellicum Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

1 brokerages have issued 1-year price objectives for Bellicum Pharmaceuticals' stock. Their forecasts range from $17.00 to $18.00. On average, they expect Bellicum Pharmaceuticals' stock price to reach $17.50 in the next year. This suggests a possible upside of 127.6% from the stock's current price. View analysts' price targets for Bellicum Pharmaceuticals.

News stories about BLCM stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Bellicum Pharmaceuticals earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news about Bellicum Pharmaceuticals.

Bellicum Pharmaceuticals saw a increase in short interest in June. As of June 30th, there was short interest totaling 401,100 shares, an increase of 6.1% from the June 15th total of 378,200 shares. Based on an average daily volume of 111,400 shares, the days-to-cover ratio is currently 3.6 days. Approximately 8.2% of the shares of the stock are short sold. View Bellicum Pharmaceuticals' Current Options Chain.

Some companies that are related to Bellicum Pharmaceuticals include Galectin Therapeutics (GALT), Kindred Biosciences (KIN), Aytu Bioscience (AYTU), Cyclerion Therapeutics (CYCN), Scpharmaceuticals (SCPH), Aldeyra Therapeutics (ALDX), vTv Therapeutics (VTVT), Evofem Biosciences (EVFM), Cerecor (CERC), Aquestive Therapeutics (AQST), Corvus Pharmaceuticals (CRVS), Tyme Technologies (TYME), Evelo Biosciences (EVLO), Obseva (OBSV) and KITOV PHARMA LT/S (KTOV). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), Cyberark Software (CYBR), TransEnterix (TRXC), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), ACADIA Pharmaceuticals (ACAD) and FireEye (FEYE).

(BLCM) raised $101 million in an initial public offering (IPO) on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BLCM stock can currently be purchased for approximately $7.69.

Bellicum Pharmaceuticals has a market capitalization of $38.83 million and generates $7.14 million in revenue each year. The biopharmaceutical company earns $-112,480,000.00 in net income (profit) each year or ($19.91) on an earnings per share basis. Bellicum Pharmaceuticals employs 173 workers across the globe.

The official website for Bellicum Pharmaceuticals is www.bellicum.com.

Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company can be reached via phone at 832-384-1100 or via email at [email protected]